Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars
Pearce IP BioBlast®: w/e 12 November 2021

Pearce IP BioBlast®: w/e 12 November 2021

09 Nov 21 | Coherus BioSciences reported its Q3 2021 financial results. Coherus announced that FDA review of CHS-201 (proposed adalimumab biosimilar) is advancing towards the target action date in December 2021. Coherus also disclosed that the FDA has accepted the BLA...
Pearce IP BioBlast®: w/e 12 November 2021

Pearce IP BioBlast®: w/e 05 November 2021

01 Nov 21 | The International Generic and Biosimilar Medicines Association called on all stakeholders ahead of its second Global Biosimilars Week to join the Biosimilars Movement on Advancing Access. The campaign seeks to gather useful ideas, experience, information...
Pearce IP BioBlast®: w/e 12 November 2021

Pearce IP BioBlast®: w/e 29 October 2021

22 Oct 21 | Biocon released its Q2 2022 financial results, reporting a 10% increase in biosimilars revenue year on year. 22 Oct 21 | Chugai Pharmaceutical announced that it will construct a new manufacturing facility in Tokyo to produce biopharmaceuticals for early...
Pearce IP BioBlast®: w/e 12 November 2021

Pearce IP BioBlast®: w/e 22 October 2021

14 Oct 21 | Gan & Lee Pharmaceuticals announced the completion of two Ph III studies of its proposed insulin glargine biosimilar. 15 Oct 21 | US | Roche announced that the FDA has approved Tecentriq® (atezolizumab) as adjuvant treatment, following surgery and...
Pearce IP BioBlast®: w/e 12 November 2021

Pearce IP BioBlast®: w/e 15 October 2021

05 Oct 21 | EU | Celltrion announced that it has submitted a Marketing Authorisation Application to the EMA seeking approval of regdanvimab for the treatment of COVID-19 in adults who do not require supplemental oxygen therapy and who are at increased risk of...